GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (NAS:CAPR) » Definitions » PS Ratio

Capricor Therapeutics (Capricor Therapeutics) PS Ratio : 5.85 (As of Apr. 29, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Capricor Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Capricor Therapeutics's share price is $5.31. Capricor Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.91. Hence, Capricor Therapeutics's PS Ratio for today is 5.85.

The historical rank and industry rank for Capricor Therapeutics's PS Ratio or its related term are showing as below:

CAPR' s PS Ratio Range Over the Past 10 Years
Min: 2.41   Med: 16.83   Max: 671.11
Current: 5.86

During the past 13 years, Capricor Therapeutics's highest PS Ratio was 671.11. The lowest was 2.41. And the median was 16.83.

CAPR's PS Ratio is ranked better than
62.24% of 993 companies
in the Biotechnology industry
Industry Median: 8.99 vs CAPR: 5.86

Capricor Therapeutics's Revenue per Sharefor the three months ended in Dec. 2023 was $0.39. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.91.

Warning Sign:

Capricor Therapeutics Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Capricor Therapeutics was 803.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 260.90% per year. During the past 5 years, the average Revenue per Share Growth Rate was -2.70% per year.

During the past 13 years, Capricor Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 260.90% per year. The lowest was -73.10% per year. And the median was -37.90% per year.

Back to Basics: PS Ratio


Capricor Therapeutics PS Ratio Historical Data

The historical data trend for Capricor Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Capricor Therapeutics PS Ratio Chart

Capricor Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.72 171.50 266.36 37.12 5.20

Capricor Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.12 19.10 12.71 6.21 5.20

Competitive Comparison of Capricor Therapeutics's PS Ratio

For the Biotechnology subindustry, Capricor Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Capricor Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's PS Ratio falls into.



Capricor Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Capricor Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=5.31/0.907
=5.85

Capricor Therapeutics's Share Price of today is $5.31.
Capricor Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.91.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Capricor Therapeutics  (NAS:CAPR) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Capricor Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Capricor Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Capricor Therapeutics (Capricor Therapeutics) Business Description

Traded in Other Exchanges
Address
10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
Executives
David B Musket director C/O CONOR MEDSYSTEMS, INC., 1003 HAMILTON COURT, MENLO PARK CA 94025
Collier Earl M Jr director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Paul Gisbert Auwaerter director C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Mike Kelliher director C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Philip J Gotwals director C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Xavier Avat officer: CHIEF BUSINESS OFFICER 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Karimah Es Sabar director C/O 8840 WILSHIRE BOULEVARD, 2ND FLOOR, BEVERLY HILLS CA 90211
Linda Marban director, officer: CHIEF EXECUTIVE OFFICER C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Dunbar George W Jr director C/O COMPETITIVE TECHNOLOGIES, INC., 777 COMMERCE DRIVE, SUITE 100, FAIRFIELD CT 06825
Karen Krasney officer: EVP, GENERAL COUNSEL C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Anthony Bergmann officer: CHIEF FINANCIAL OFFICER C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Louis Manzo director C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Cedars Sinai Medical Center 10 percent owner 8700 BEVERLY BLVD, LOS ANGELES CA 90048-1865
St. John Edward A. 10 percent owner 2560 LORD BALTIMORE DRIVE, BALTIMORE MD 21244
Leland Gershell officer: Chief Financial Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., STE 306, NEW YORK NY 10022

Capricor Therapeutics (Capricor Therapeutics) Headlines

From GuruFocus

Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer

By GuruFocusNews GuruFocusNews 07-04-2022